# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-appro...
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Eu...
RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $300 price target.
Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product ...
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data fr...